Drug Royalty III is a closed private equity fund managed by DRI Capital.
DRI Capital has bought the rights to a certain drug from Rush University Medical Center with about $42m from its Drug Royalty III fund.
Read more news concerning Drug Royalty III
DRI Capital is a private equity general partner firm headquartered in Toronto, ON, Canada.
View full profile
Registration is fast, free and easy
Already a member?